Pacific Biosciences Grants Equity Incentive Award to New Employee
Pacific Biosciences (NASDAQ: PACB) announced the grant of stock options and restricted stock units to a new employee under its 2020 Inducement Equity Incentive Plan. The grant includes 80,000 shares as stock options and 40,000 shares as RSUs, effective April 19, 2021. The options have an exercise price of $29.61, matching the closing stock price on the effective date. Vesting for the options occurs over four years, while RSUs vest annually over four years. This initiative aims to attract talent to the company in compliance with Nasdaq rules.
- Grant of 80,000 stock options and 40,000 RSUs indicates commitment to attracting talent.
- Options have an exercise price equal to the market price, aligning interests with shareholders.
- None.
MENLO PARK, Calif., April 22, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (“Pacific Biosciences” or the “Company”), a leading provider of high-quality sequencing of genomes, transcriptomes, and epigenomes, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of 80,000 shares of Pacific Biosciences common stock and restricted stock units (“RSUs”) covering 40,000 shares of Pacific Biosciences common stock to a recently hired employee under the Pacific Biosciences 2020 Inducement Equity Incentive Plan (the “2020 Inducement Plan”) effective on April 19, 2021.
The 2020 Inducement Plan is used exclusively to grant equity awards to individuals who were not previously an employee or non-employee director of Pacific Biosciences as an inducement material to such individual’s entering into employment with Pacific Biosciences in accordance with Nasdaq Marketplace Rule 5635(c)(4).
The options have an exercise price of
About Pacific Biosciences
Pacific Biosciences of California, Inc. (NASDAQ: PACB) is empowering life scientists with highly accurate long-read sequencing. The company’s innovative instruments are based on Single Molecule, Real-Time (SMRT®) Sequencing technology, which delivers a comprehensive view of genomes, transcriptomes, and epigenomes, enabling access to the full spectrum of genetic variation in any organism. Cited in thousands of peer-reviewed publications, PacBio® sequencing systems are in use by scientists around the world to drive discovery in human biomedical research, plant and animal sciences, and microbiology.
Contact
Investors: Todd Friedman
650.521.8450
ir@pacificbiosciences.com
FAQ
What stock options were granted by PACB?
What is the exercise price of the stock options granted by PACB?
When were the stock options and RSUs granted by Pacific Biosciences?
What is the vesting schedule for the stock options granted by PACB?